GlassScriptPhysician profile
Jose Rafael Pena
NPI 1437170008
$2,674.56
in general payments reported to CMS, 2019-2025
32 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $161 · 2021: $183 · 2022: $433 · 2023: $350 · 2024: $730 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $301.02 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $294.74 | 2019-2025 | |
| Lilly USA, LLC | $219.72 | 2019-2025 | Jardiance, Kisunla, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.19 | 2019-2025 | Jardiance |
| Si-Bone, INC. | $173.26 | 2024 | |
| Sumitomo Pharma America, INC. | $144.37 | 2024 | Gemtesa |
| Amgen INC. | $135.11 | 2022-2025 | Repatha, Repatha, Otezla |
| Mannkind Corporation | $131.87 | 2019-2022 | |
| Boston Scientific Corporation | $129.37 | 2021 | |
| Genzyme Corporation | $122.83 | 2022 | |
| Exact Sciences Corporation | $107.52 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $85.76 | 2023-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $69.37 | 2022-2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $65.57 | 2021-2022 | |
| Shield Therapeutics INC | $54.41 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $46.00 | 2019 | |
| Topcon Healthcare Solutions, INC. | $41.29 | 2020 | |
| Dexcom, INC. | $41.02 | 2022-2023 | Dexcom G6 Transmitter |
| Evoke Pharma, INC. | $40.28 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.28 | 2024 | |
| Electromed, INC. | $29.77 | 2025 | Smartvest |
| Nevro Corp. | $29.52 | 2024 | Senza |
| Medtronic Vascular, INC. | $25.42 | 2020 | |
| Krystal Biotech INC | $22.36 | 2023 | Vyjuvek |
| Alnylam Pharmaceuticals INC. | $22.22 | 2023 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $21.29 | 2022 | |
| Allergan, INC. | $20.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.44 | 2021 | |
| Abbvie INC. | $16.98 | 2025 | |
| Amarin Pharma, INC. | $16.76 | 2019 | |
| Glaxosmithkline, LLC. | $15.23 | 2021 | |
| Scilex Pharmaceuticals INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.